S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NYSE:NVS

Novartis - NVS Price Target & Analyst Ratings

$76.01
-0.56 (-0.73%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$75.93
$77.11
50-Day Range
$74.61
$87.43
52-Week Range
$74.09
$94.26
Volume
2.26 million shs
Average Volume
2.61 million shs
Market Capitalization
$168.18 billion
P/E Ratio
7.43
Dividend Yield
2.82%
Price Target
$87.09

Novartis Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 14 Analyst Ratings

Consensus Analyst Price Target

$85.00
11.83% Upside
High Prediction$85.00
Average Prediction$85.00
Low Prediction$85.00
TypeCurrent
10/2/21 to 10/2/22
1 Month Ago
9/2/21 to 9/2/22
3 Months Ago
7/4/21 to 7/4/22
1 Year Ago
10/2/20 to 10/2/21
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
Hold
10 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
3 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$85.00$85.00$85.00$108.50
Predicted Upside11.83% Upside2.77% Upside3.25% Upside19.71% Upside
Get Novartis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.


NVS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novartis Stock vs. The Competition

TypeNovartisMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.68
2.49
Consensus RatingHoldBuyHold
Predicted Upside11.83% Upside1,097.69% Upside35.92% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
516
61.94%
Underperform Votes
317
38.06%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
852
68.43%
Avg. Underperform Votes
393
31.57%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/29/2022Oddo Bhf
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Martial Descoutures
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ NeutralCHF 88
9/15/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Dominic Lunn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform
9/14/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
9/8/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetCHF 97 ➝ CHF 88
9/7/2022Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Evans
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ BuyCHF 90
7/20/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ UnderweightCHF 80 ➝ CHF 81
6/29/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetCHF 80 ➝ CHF 75
6/3/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
5/9/2022Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
4/27/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ NeutralCHF 85 ➝ CHF 88
4/14/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetCHF 80 ➝ CHF 85
2/28/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
2/3/2022Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetCHF 107 ➝ CHF 105
1/10/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
12/14/2021Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Simon Baker
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
12/6/2021Exane BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Richard Parkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ NeutralCHF 85
12/3/2021Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jeanjacques Le
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$115.00 ➝ $85.00+6.32%
3/22/2021Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
3/16/2021Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
2/1/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$110.00 ➝ $105.00+16.06%
4/3/2020The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Keyur Parekh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$116.00+38.69%
2/25/2020Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
(Data available from 10/2/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NVS Price Target - Frequently Asked Questions

What is Novartis's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Novartis stock is Hold based on the current 2 sell ratings, 10 hold ratings and 2 buy ratings for NVS. The average twelve-month price prediction for Novartis is $85.00 with a high price target of $85.00 and a low price target of $85.00. Learn more on NVS's analyst rating history.

Do Wall Street analysts like Novartis more than its competitors?

Analysts like Novartis less than other Medical companies. The consensus rating for Novartis is Hold while the average consensus rating for medical companies is Buy. Learn more on how NVS compares to other companies.

Do MarketBeat users like Novartis more than its competitors?

MarketBeat users like Novartis less than other Medical companies. 61.94% of MarketBeat users gave Novartis an outperform vote while medical companies recieve an average of 66.53% outperform votes by MarketBeat users.

Is Novartis being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Novartis's stock had 3 downgrades and 1 upgrade by analysts.

Does Novartis's stock price have much upside?

According to analysts, Novartis's stock has a predicted upside of 4.45% based on their 12-month price targets.

What analysts cover Novartis?

Stock Ratings Reports and Tools

This page (NYSE:NVS) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.